New York, January 5, 2026, 14:30 (EST) — Regular session
- BridgeBio shares fell about 7.5% in afternoon trading after an early jump.
- The company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
- Investors are watching a Jan. 9 webinar ahead of expected Q1 Phase 3 achondroplasia data.
BridgeBio Pharma shares slid 7.5% to $72.34 in afternoon trading on Monday after opening at $78.44 and touching $79.24 earlier in the session. The drop outpaced a roughly 2.2% decline in the SPDR S&P Biotech ETF, a broad gauge of U.S. biotech stocks.
The move lands just ahead of a dense stretch of biotech investor events that can reshape positioning at the start of the year. For BridgeBio, the calendar puts fresh focus on a late-stage growth program and the company’s next set of talking points on its commercial heart franchise.
BridgeBio will host an investor webinar on Friday, Jan. 9 at 8:00 a.m. ET with Janet Legare, a University of Wisconsin pediatric specialist and an investigator in PROPEL 3, the company’s registrational Phase 3 study of infigratinib in children with achondroplasia, the company said. Management said topline results — the first look at the main trial endpoints — are expected in the first quarter of 2026. 1
Achondroplasia is the most common form of dwarfism, and competition is already established: BioMarin markets Voxzogo, which the U.S. FDA approved to improve growth in children with the condition. That means investors are likely to press for clarity on how an oral rival could differentiate on efficacy, safety and convenience.
Separately, BridgeBio said co-founder and CEO Neil Kumar will present at the J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12 at 7:30 a.m. PT, with a webcast available via the company’s investor site. 2
BridgeBio’s broader investment case has been anchored by Attruby, its FDA-approved treatment for transthyretin amyloid cardiomyopathy, a progressive condition in which abnormal protein deposits can lead to heart failure. When the drug was cleared in late 2024, Scotiabank analyst Greg Harrison said, “It is better for the patient community to have more options,” in comments on competition in the market dominated by Pfizer’s Vyndaqel. 3
From here, investors will be listening for any tightening of the timeline around PROPEL 3 and for updates on how management is framing 2026 priorities as it balances late-stage R&D with a commercial rollout. With the J.P. Morgan conference often used to reset expectations, even incremental changes in tone can move high-beta biotech shares.
But the next readout still carries binary risk: PROPEL 3 could miss its primary goal or raise safety questions, and the achondroplasia market is already served by an approved therapy, raising the bar for a new entrant. On the commercial side, Attruby faces entrenched competition and the usual scrutiny around pricing, reimbursement and switching behavior in chronic cardiology care.
